Human Serum Fetuin A/alpha2HS-glycoprotein Level is Associated with Long-term Survival in Patients with Alcoholic Liver Cirrhosis, Comparison with the Child-Pugh and MELD Scores

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2007 Mar 31

PMID 17394649

Citations 14

Authors

Laszlo Kalabay

Laszlo Graf

Krisztian Voros

Laszlo Jakab

Zsuzsa Benko

Laszlo Telegdy

Bela Fekete

Zoltan Prohaszka

George Fust

Affiliations

Soon will be listed here.

Abstract

Background: Serum concentration of fetuin A/alpha2HS-glycoprotein (AHSG) is a good indicator of liver cell function and 1-month mortality in patients with alcoholic liver cirrhosis and liver cancer. We intended to determine whether decreased serum AHSG levels are associated with long-term mortality and whether the follow-up of serum AHSG levels can add to the predictive value of the Child-Pugh (CP) and MELD scores.

Methods: We determined serum AHSG concentrations in 89 patients by radial immunodiffusion. Samples were taken at the time of enrollment and in the 1st, 3rd, 6th, and the 12th month thereafter.

Results: Forty-one patients died during the 1-year follow-up period, 37 of them had liver failure. Data of these patients were analysed further. Deceased patients had lower baseline AHSG levels than the 52 patients who survived (293 +/- 77 vs. 490 +/- 106 microg/ml, mean +/- SD, p < 0.001). Of all laboratory parameters serum AHSG level, CP and MELD scores showed the greatest difference between deceased and survived patients. The cutoff AHSG level 365 microg/ml could differentiate between deceased and survived patients (AUC: 0.937 +/- 0.025, p < 0.001, sensitivity: 0.865, specificity: 0.942) better than the MELD score of 20 (AUC: 0.739 +/- 0.052, p < 0.001, sensitivity: 0.595, specificity: 0.729). Initial AHSG concentrations < 365 microg/ml were associated with high mortality rate (91.4%, relative risk: 9.874, 95% C.I.: 4.258-22.898, p < 0.001) compared to those with > or = 365 microg/ml (9.3%). Fourteen out of these 37 fatalities occurred during the first month of observation. During months 1-12 low AHSG concentration proved to be a strong indicator of mortality (relative risk: 9.257, 95% C.I.: 3.945-21.724, p < 0.001). Multiple logistic regression analysis indicated that decrease of serum AHSG concentration was independent of all variables that differed between survived and deceased patients during univariate analysis. Multivariate analysis showed that correlation of low serum AHSG levels with mortality was stronger than that with CP and MELD scores. Patients with AHSG < 365 microg/ml had significantly shortened survival both in groups with MELD < 20 and MELD > or = 20 (p < 0.0001 and p = 0.0014, respectively).

Conclusion: Serum AHSG concentration is a reliable and sensitive indicator of 1-year mortality in patients with alcoholic liver cirrhosis that compares well to the predictive value of CP score and may further improve that of MELD score.

Citing Articles

Serum fetuin-A is decreased in cirrhotic patients with Wilson's disease.

Voros K, Markus B, Atzel K, Szalay F, Graf L, Nemeth D PLoS One. 2023; 18(3):e0282801.

PMID: 36881584 PMC: 9990947. DOI: 10.1371/journal.pone.0282801.

Transcriptomic Profile of the Mouse Postnatal Liver Development by Single-Nucleus RNA Sequencing.

Xu J, Hao S, Shi Q, Deng Q, Jiang Y, Guo P Front Cell Dev Biol. 2022; 10:833392.

PMID: 35465320 PMC: 9019599. DOI: 10.3389/fcell.2022.833392.

Proteomic Signatures of Lifestyle Risk Factors for Cardiovascular Disease: A Cross-Sectional Analysis of the Plasma Proteome in the Framingham Heart Study.

Corlin L, Liu C, Lin H, Leone D, Yang Q, Ngo D J Am Heart Assoc. 2020; 10(1):e018020.

PMID: 33372532 PMC: 7955453. DOI: 10.1161/JAHA.120.018020.

Can Fetuin-A, CRP, and WBC Levels Be Predictive Values in the Diagnosis of Acute Appendicitis in Children with Abdominal Pain?.

Guney C, Coskun A Healthcare (Basel). 2019; 7(4).

PMID: 31547519 PMC: 6956327. DOI: 10.3390/healthcare7040110.

Concentrations of fetuin-A, osteoprotegerin and α-Klotho in patients with alcoholic liver cirrhosis.

Prystupa A, Dabrowska A, Sak J, Tarach J, Torun-Jurkowska A, Lachowska-Kotowska P Exp Ther Med. 2016; 12(5):3464-3470.

PMID: 27882180 PMC: 5103841. DOI: 10.3892/etm.2016.3754.

References

Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C . A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33(2):464-70. DOI: 10.1053/jhep.2001.22172. View

Biggins S, Kim W, Terrault N, Saab S, Balan V, Schiano T . Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006; 130(6):1652-60. DOI: 10.1053/j.gastro.2006.02.010. View

Kalabay L, Nemesanszky E, Csepregi A, Pusztay M, David K, Horvath G . Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-alpha2b. Int Immunol. 2003; 16(1):51-4. DOI: 10.1093/intimm/dxh024. View

Christensen E . Prognostic models including the Child-Pugh, MELD and Mayo risk scores--where are we and where should we go?. J Hepatol. 2004; 41(2):344-50. DOI: 10.1016/j.jhep.2004.06.005. View

Dickson I, Poole A, Veis A . Localisation of plasma alpha2HS glycoprotein in mineralising human bone. Nature. 1975; 256(5516):430-2. DOI: 10.1038/256430a0. View

Triffitt J, Gebauer U, Ashton B, Owen M, Reynolds J . Origin of plasma alpha2HS-glycoprotein and its accumulation in bone. Nature. 1976; 262(5565):226-7. DOI: 10.1038/262226a0. View

Lebreton J, Joisel F, Raoult J, Lannuzel B, Rogez J, Humbert G . Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest. 1979; 64(4):1118-29. PMC: 372224. DOI: 10.1172/JCI109551. View

DAVEAU M, Julen N, Hiron M, Arnaud P, Lebreton J . The synthesis of human alpha-2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett. 1988; 241(1-2):191-4. DOI: 10.1016/0014-5793(88)81059-7. View

DAVEAU M, Davrinche C, Djelassi N, Lemetayer J, Julen N, Hiron M . Partial hepatectomy and mediators of inflammation decrease the expression of liver alpha 2-HS glycoprotein gene in rats. FEBS Lett. 1990; 273(1-2):79-81. DOI: 10.1016/0014-5793(90)81055-s. View

10.

Jakab L, Kalabay L, Pozsonyi T, Cseh K . The effect of the alpha 2-HS-glycoprotein on the mitogen-induced lymphoblastic transformation and IL-2 production. Acta Physiol Hung. 1991; 77(1):25-31. View

11.

Srinivas P, Wagner A, Reddy L, Deutsch D, Leon M, Goustin A . Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol. 1993; 7(11):1445-55. DOI: 10.1210/mend.7.11.7906861. View

12.

Demetriou M, Binkert C, Sukhu B, Tenenbaum H, Dennis J . Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem. 1996; 271(22):12755-61. DOI: 10.1074/jbc.271.22.12755. View

13.

Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W . The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem. 1996; 271(34):20789-96. DOI: 10.1074/jbc.271.34.20789. View

14.

Ohnishi T, Nakamura O, Arakaki N, Daikuhara Y . Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary culture in the presence of human hepatocyte-growth factor. Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Eur J Biochem. 1997; 243(3):753-61. DOI: 10.1111/j.1432-1033.1997.00753.x. View

15.

Kalabay L, Szalay F, Nemesanszky E, Telegdy L, Jakab L, Romics L . Decreased serum alfa2-HS-glycoprotein concentration in patients with primary biliary cirrhosis. J Hepatol. 1997; 26(6):1426-7. DOI: 10.1016/s0168-8278(97)80483-7. View

16.

Jahnen-Dechent W, Schinke T, Trindl A, Muller-Esterl W, Sablitzky F, Kaiser S . Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem. 1998; 272(50):31496-503. DOI: 10.1074/jbc.272.50.31496. View

17.

Kalabay L, Chavin K, Lebreton J, Robinson K, BUSE M, Arnaud P . Human recombinant alpha 2-HS glycoprotein is produced in insect cells as a full length inhibitor of the insulin receptor tyrosine kinase. Horm Metab Res. 1998; 30(1):1-6. DOI: 10.1055/s-2007-978822. View

18.

Cholongitas E, Papatheodoridis G, Vangeli M, Terreni N, Patch D, Burroughs A . Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?. Aliment Pharmacol Ther. 2005; 22(11-12):1079-89. DOI: 10.1111/j.1365-2036.2005.02691.x. View

19.

Kalabay L, Jakab L, Prohaszka Z, Fust G, Benko Z, Telegdy L . Human fetuin/alpha2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur J Gastroenterol Hepatol. 2002; 14(4):389-94. DOI: 10.1097/00042737-200204000-00009. View